PRC
CHRS icon

Pearl River Capital’s Coherus Oncology CHRS Stock Holding History

Pearl River Capital’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-400
Closed -$6K – 300
2019
Q1 		$6K Sell
400
-600
-60% -$8.01K 0.01% 319
2018
Q4 		$9K Buy
+1,000
New +$11.6K 0.04% 593

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Pearl River Capital's CHRS Position: Q2 2019 in Review

Pearl River Capital sold out of Coherus Oncology (CHRS) in Q2 2019, closing a stake of 400 shares — an estimated $6K sold.

Pearl River Capital first reported a position in CHRS in Q4 2018 and held it in 2 quarters. The position peaked at $9K in Q4 2018. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2019.

  • Pearl River Capital reported no remaining Coherus Oncology position as of Q2 2019 after selling out during the quarter.
  • Pearl River Capital sold 400 Coherus Oncology shares in Q2 2019, an estimated $6K.
  • Pearl River Capital first reported a position in Coherus Oncology in Q4 2018 and held it in 2 quarters.
  • Pearl River Capital's Coherus Oncology position peaked at $9K in Q4 2018.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2019.

Based on Pearl River Capital's 13F filing for Q2 2019, filed 12 Aug 2019.